Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CD23

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: CD23. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2006-002850-31 Sponsor Protocol Number: AP3005 Start Date*: 2006-08-31
    Sponsor Name:TopoTarget A/S
    Full Title: APO866 for B-Cell Leukaemia. An open phase I/II clinical study assessing the safety and tolerability of APO866 in patients with refractory B-cell lymphocytic leukaemia not amenable to allogeneic he...
    Medical condition: The medical condition for this clinical trial is B. cell chronic lymphocytic leukemia.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003894 B-cell chronic lymphocytic leukaemia/prolymphocytic leukaemia/small lymphocytic lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011433-27 Sponsor Protocol Number: ML22489 Start Date*: 2009-11-04
    Sponsor Name:Roche Romania SRL
    Full Title: A phase II multicenter open-label study of MabThera (Rituximab) addition to regularly prescribed chemotherapy in patients with untreated Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000243-10 Sponsor Protocol Number: Hx-CD20-407 Start Date*: 2007-05-16
    Sponsor Name:Glaxo SmithKline Research and Development Limited
    Full Title: An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previ...
    Medical condition: B-cell Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006915-61 Sponsor Protocol Number: CAM-CLL1 Start Date*: 2007-04-03
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: Prospective Randomized Trial of Immediate Treatment with Campath versus Deferred Therapy in Patients with Previously Untreated Binet Stage A B-Cell Chronic Lymphocytic Leukemia at High Risk for...
    Medical condition: previously untreated Binet stage A CLL patients at high risk of disease progression
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008943 Chronic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004912-43 Sponsor Protocol Number: AGMT_CLL-9 Start Date*: 2012-06-27
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with escalating starting dose of Lenalidomide and concomi...
    Medical condition: Untreated chronic lymphocytic leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004998-53 Sponsor Protocol Number: OMB116024 Start Date*: 2013-02-05
    Sponsor Name:National and Kapodistrian University of Athens
    Full Title: A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia.
    Medical condition: Relapsed or refractory Waldenström’s Macroglobulinemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004987-37 Sponsor Protocol Number: CLL-6 Start Date*: 2010-01-21
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Bendamustine Combined with Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) – A Phase I/II Trial with Concomitant Evaluation of Safety and Efficacy
    Medical condition: Pre-treated chronic lymphocytic leukaemia (B-CLL)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001430-27 Sponsor Protocol Number: CLL-5 Start Date*: 2008-08-28
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evalu...
    Medical condition: Untreated chronic lymphocytic leukaemia (B-CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003012-35 Sponsor Protocol Number: HM07/8281 Start Date*: 2012-06-12
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CL...
    Medical condition: Chronic lymphocytic leukaemia (CLL).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002601-40 Sponsor Protocol Number: CD20-0703 Start Date*: 2008-09-25
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: Open, non-controlled, multicentre, first-in-man study using escalating doses of LFB-R603 in patients with advanced stage B-Chronic lymphocytic leukemia
    Medical condition: B-Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    11 10008960 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005582-73 Sponsor Protocol Number: ACE-CL-007 Start Date*: 2015-07-03
    Sponsor Name:Acerta Pharma BV
    Full Title: A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previ...
    Medical condition: Untreated Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005530-64 Sponsor Protocol Number: ACE-CL-006 Start Date*: 2015-07-31
    Sponsor Name:Acerta Pharma BV
    Full Title: A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia
    Medical condition: High Risk Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) NL (Ongoing) BE (Completed) FR (Completed) ES (Ongoing) DK (Completed) DE (Completed) PL (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004554-30 Sponsor Protocol Number: LOXO-BTK-20020 Start Date*: 2021-06-04
    Sponsor Name:Loxo Oncology Inc
    Full Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/...
    Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-006163-31 Sponsor Protocol Number: Hx-CD20-406 Start Date*: 2006-05-16
    Sponsor Name:Genmab A/S
    Full Title: A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alem...
    Medical condition: B-cell Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10008959 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) IT (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000043-49 Sponsor Protocol Number: LOXO-BTK-20022 Start Date*: 2021-08-16
    Sponsor Name:Loxo Oncology Inc
    Full Title: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Sm...
    Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NO (Completed) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005178-43 Sponsor Protocol Number: OMB115991 Start Date*: 2012-02-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
    Medical condition: Untreated or Relapsed Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10008968 Chronic lymphocytic leukaemia stage A(0) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Prematurely Ended) BE (Completed) ES (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001573-89 Sponsor Protocol Number: D8220C00008 Start Date*: 2019-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA) FI (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017269-49 Sponsor Protocol Number: IC 2009-06 Start Date*: 2010-02-08
    Sponsor Name:INSTITUT CURIE
    Full Title: Etude de phase II d’évaluation de la toxicité et de l’efficacité d’un traitement par Tacrolimus (Prograf®) chez des patients atteints d’un lymphome diffus à grandes cellules B ou T.
    Medical condition: Lymphomes malins diffus à grandes cellules B ou T.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002204-25 Sponsor Protocol Number: 152CL202 Start Date*: 2009-04-21
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone in Subjects with P...
    Medical condition: Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008958 Chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) BE (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003820-30 Sponsor Protocol Number: HYD-HD85/45-CLL-02 Start Date*: 2016-02-22
    Sponsor Name:HYD Pharma Zrt.
    Full Title: A MULTICENTER, SINGLE ARM, OPEN LABEL, EXPLORATORY PROSPECTIVE PHASE II STUDY TO EXPLORE THE EFFICACY, SAFETY AND TOLERABILITY OF DEUTERIUM DEPLETED WATER IN PREVIOUSLY UNTREATED PATIENTS WITH ASYM...
    Medical condition: Previously untreated patients with asymptomatic chronic lymphocytic leukemia but who are at high risk of progression.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10060576 Chronic lymphoid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 18:55:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA